EP3637105A3 - Procédés permettant de prévoir le terme chez la femme enceinte - Google Patents

Procédés permettant de prévoir le terme chez la femme enceinte Download PDF

Info

Publication number
EP3637105A3
EP3637105A3 EP19196400.6A EP19196400A EP3637105A3 EP 3637105 A3 EP3637105 A3 EP 3637105A3 EP 19196400 A EP19196400 A EP 19196400A EP 3637105 A3 EP3637105 A3 EP 3637105A3
Authority
EP
European Patent Office
Prior art keywords
methods
delivery
pregnant women
predicting time
predicting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19196400.6A
Other languages
German (de)
English (en)
Other versions
EP3637105B1 (fr
EP3637105A2 (fr
EP3637105C0 (fr
Inventor
Anthony AUSIELLO
Ruben SALINAS
Michael Thompson
Daniel J. MACKEY
Kaitlyn NARDOZZI
Michael Friedman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qiagen Sciences LLC
Original Assignee
Qiagen Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qiagen Sciences LLC filed Critical Qiagen Sciences LLC
Priority to EP25214823.4A priority Critical patent/EP4699616A3/fr
Publication of EP3637105A2 publication Critical patent/EP3637105A2/fr
Publication of EP3637105A3 publication Critical patent/EP3637105A3/fr
Application granted granted Critical
Publication of EP3637105B1 publication Critical patent/EP3637105B1/fr
Publication of EP3637105C0 publication Critical patent/EP3637105C0/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G01N33/54388—Immunochromatographic test strips based on lateral flow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • A61B10/0045—Devices for taking samples of body liquids
    • A61B2010/0074—Vaginal or cervical secretions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/471—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP19196400.6A 2013-01-02 2013-12-23 Procédés permettant de prévoir le terme chez la femme enceinte Active EP3637105B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP25214823.4A EP4699616A3 (fr) 2013-01-02 2013-12-23 Procédés de prédiction du temps de livraison chez des femmes enceintes

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361748310P 2013-01-02 2013-01-02
US201361909238P 2013-11-26 2013-11-26
PCT/US2013/077541 WO2014107373A1 (fr) 2013-01-02 2013-12-23 Procédés permettant de prévoir le terme chez une femme enceinte
EP13870051.3A EP2941644B1 (fr) 2013-01-02 2013-12-23 Procédés permettant de prévoir le terme chez une femme enceinte

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP13870051.3A Division EP2941644B1 (fr) 2013-01-02 2013-12-23 Procédés permettant de prévoir le terme chez une femme enceinte

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP25214823.4A Division EP4699616A3 (fr) 2013-01-02 2013-12-23 Procédés de prédiction du temps de livraison chez des femmes enceintes

Publications (4)

Publication Number Publication Date
EP3637105A2 EP3637105A2 (fr) 2020-04-15
EP3637105A3 true EP3637105A3 (fr) 2020-07-29
EP3637105B1 EP3637105B1 (fr) 2025-11-12
EP3637105C0 EP3637105C0 (fr) 2025-11-12

Family

ID=51062428

Family Applications (3)

Application Number Title Priority Date Filing Date
EP13870051.3A Active EP2941644B1 (fr) 2013-01-02 2013-12-23 Procédés permettant de prévoir le terme chez une femme enceinte
EP25214823.4A Pending EP4699616A3 (fr) 2013-01-02 2013-12-23 Procédés de prédiction du temps de livraison chez des femmes enceintes
EP19196400.6A Active EP3637105B1 (fr) 2013-01-02 2013-12-23 Procédés permettant de prévoir le terme chez la femme enceinte

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP13870051.3A Active EP2941644B1 (fr) 2013-01-02 2013-12-23 Procédés permettant de prévoir le terme chez une femme enceinte
EP25214823.4A Pending EP4699616A3 (fr) 2013-01-02 2013-12-23 Procédés de prédiction du temps de livraison chez des femmes enceintes

Country Status (9)

Country Link
US (4) US20140234987A1 (fr)
EP (3) EP2941644B1 (fr)
JP (1) JP6465812B2 (fr)
CN (2) CN107727841B (fr)
AU (1) AU2013371462B2 (fr)
BR (1) BR112015016027A2 (fr)
CA (1) CA2897053C (fr)
ES (2) ES3057344T3 (fr)
WO (1) WO2014107373A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2204654B1 (fr) * 2002-08-13 2012-12-12 N-Dia, Inc. Utilisation des dispositifs et procédés pour détecter du liquide amniotique dans les sécrétions vaginales
WO2016208466A1 (fr) * 2015-06-22 2016-12-29 ウシオ電機株式会社 Procédé de détection d'une substance d'intérêt
US10656164B2 (en) 2016-12-22 2020-05-19 Qiagen Sciences, Llc Screening asymptomatic pregnant woman for preterm birth
US10935555B2 (en) 2016-12-22 2021-03-02 Qiagen Sciences, Llc Determining candidate for induction of labor
KR101965299B1 (ko) * 2017-11-14 2019-04-03 주식회사 수젠텍 조립형 블롯 스트립 디바이스
MX2022003307A (es) * 2019-09-22 2022-04-12 Ecole Polytechnique Fed Lausanne Epfl Dispositivo y metodo para la valoracion del riesgo de nacimiento prematuro.
KR20230159985A (ko) * 2022-05-16 2023-11-23 삼성전자주식회사 반도체 소자 검사 장치, 이를 이용한 반도체 소자 검사 방법 및 이를 이용한 반도체 소자 제조 방법
CN121713066A (zh) * 2023-12-28 2026-03-20 深圳华大基因股份有限公司 与早产相关的蛋白标志物、早产预测模型的构建方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114610B2 (en) * 2002-08-13 2012-02-14 N-Dia, Inc. Devices and methods for detecting amniotic fluid in vaginal secretions

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622871A (en) 1987-04-27 1997-04-22 Unilever Patent Holdings B.V. Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
NL7807532A (nl) 1978-07-13 1980-01-15 Akzo Nv Metaal-immunotest.
NL8000173A (nl) 1980-01-11 1981-08-03 Akzo Nv Toepassing van in water dispergeerbare, hydrofobe kleurstoffen als label in immunochemische testen.
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US5073484A (en) 1982-03-09 1991-12-17 Bio-Metric Systems, Inc. Quantitative analysis apparatus and method
US4594327A (en) 1983-11-02 1986-06-10 Syntex (U.S.A.) Inc. Assay method for whole blood samples
US4595661A (en) 1983-11-18 1986-06-17 Beckman Instruments, Inc. Immunoassays and kits for use therein which include low affinity antibodies for reducing the hook effect
US4703017C1 (en) 1984-02-14 2001-12-04 Becton Dickinson Co Solid phase assay with visual readout
US4632901A (en) 1984-05-11 1986-12-30 Hybritech Incorporated Method and apparatus for immunoassays
US4978503A (en) 1984-06-13 1990-12-18 Ares-Serono Research & Development Limited Partnership Devices for use in chemical test procedures
US4806312A (en) 1985-08-28 1989-02-21 Miles Inc. Multizone analytical element having detectable signal concentrating zone
SU1387974A1 (ru) * 1985-11-05 1988-04-15 Ивановский научно-исследовательский институт материнства и детства Способ диагностики гипоксии плода у беременных
DE3544929C1 (de) 1985-12-19 1987-05-07 Messerschmitt Boelkow Blohm Gehaeuse zum Schutz von Sprengladungen
US4906439A (en) 1986-03-25 1990-03-06 Pb Diagnostic Systems, Inc. Biological diagnostic device and method of use
US4959305A (en) 1986-06-18 1990-09-25 Miles Inc. Reversible immobilization of assay reagents in a multizone test device
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5156952A (en) 1986-11-07 1992-10-20 Syntex (U.S.A.) Inc. Qualitative immunochromatographic method and device
US5030558A (en) 1986-11-07 1991-07-09 Syntex (U.S.A.) Inc. Qualitative immunochromatographic method and device
US4770853A (en) 1986-12-03 1988-09-13 New Horizons Diagnostics Corporation Device for self contained solid phase immunodiffusion assay
EP0280559B1 (fr) 1987-02-27 1993-10-20 EASTMAN KODAK COMPANY (a New Jersey corporation) Essai immunologique d'agglutination et trousse de réactifs pour la détermination d'une espèce immunollogique polyvalente utilisant une solution saline de nettoyage tamponnée
DE3882058T2 (de) 1987-02-27 1994-01-13 Eastman Kodak Co Immunoreaktives Reagens, Verfahren zu seiner Herstellung und seine Verwendung zur Bestimmung einer immunoreaktiven Spezies.
US4918025A (en) 1987-03-03 1990-04-17 Pb Diagnostic Systems, Inc. Self contained immunoassay element
US5137808A (en) 1987-04-07 1992-08-11 Syntex (U.S.A.) Inc. Immunoassay device
US4857453A (en) 1987-04-07 1989-08-15 Syntex (U.S.A.) Inc. Immunoassay device
ES2150428T3 (es) 1987-04-27 2000-12-01 Unilever Nv Ensayos de union especifica.
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US4943522A (en) 1987-06-01 1990-07-24 Quidel Lateral flow, non-bibulous membrane assay protocols
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
CA1337394C (fr) 1987-11-17 1995-10-24 Nelson N. H. Teng Test a prelevement vaginal et reactifs
US5114673A (en) 1988-01-21 1992-05-19 Boehringer Mannheim Corporaton Apparatus for determination of a component in a sample
US4952517A (en) 1988-02-08 1990-08-28 Hygeia Sciences, Inc. Positive step immunoassay
NO164622C (no) 1988-05-11 1990-10-24 Tore Lindmo Binaer immunometrisk partikkelbasert metode for maaling av spesifikke serum-antigener ved hjelp av vaeskestroemsmikrofotometri og et ferdigpreparert maaloppsett derav.
EP0413763B1 (fr) 1988-06-13 1996-11-06 American Biogenetic Sciences, Inc. Procede de production d'anticorps monoclonaux a l'aide d'un animal non porteur de germes
US5051237A (en) 1988-06-23 1991-09-24 P B Diagnostic Systems, Inc. Liquid transport system
EP0347967A1 (fr) 1988-06-23 1989-12-27 Agfa-Gevaert N.V. Matériau d'enregistrement photosensible apte à l'emploi dans l'électrophotographie
US5037735A (en) 1988-06-24 1991-08-06 Microgenics Corporation Visual discrimination qualitative enzyme complementation assay
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5232833A (en) 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
US5252459A (en) 1988-09-23 1993-10-12 Abbott Laboratories Indicator reagents, diagnostic assays and test kits employing organic polymer latex particles
IT1227293B (it) 1988-10-06 1991-04-05 Boehringer Biochemia Srl Dispositivo e metodo per la diagnosi di gravidanza
WO1990010061A1 (fr) 1989-03-02 1990-09-07 Griffith University Diamine oxidase et examen permettant de detecter une rupture de la membrane amniotique chez les mammiferes en etat de grossesse
ES2063348T3 (es) 1989-04-11 1995-01-01 Ars Holding 89 Nv Vehiculo de ensayo multianalitico.
US5147609A (en) 1989-05-19 1992-09-15 Pb Diagnostic Systems, Inc. Assay element
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
US5141871A (en) 1990-05-10 1992-08-25 Pb Diagnostic Systems, Inc. Fluid dispensing system with optical locator
FI86777C (fi) 1990-12-31 1992-10-12 Medix Biochemica Ab Oy Foerfarande foer diagnosticering av bristningen av fosterhinnorna samt reagensfoerpackning foer anvaendning daervid
US5138868A (en) 1991-02-13 1992-08-18 Pb Diagnostic Systems, Inc. Calibration method for automated assay instrument
FI94181C (fi) 1992-06-29 1995-07-25 Medix Biochemica Ab Oy Diagnostinen menetelmä synnytysajankohdan ennustamiseksi sekä siihen käytettävä reagenssipakkaus
US5354692A (en) 1992-09-08 1994-10-11 Pacific Biotech, Inc. Analyte detection device including a hydrophobic barrier for improved fluid flow
US5308775A (en) 1992-09-15 1994-05-03 Abbott Laboratories Assay devices for concurrently detecting an analyte and confirming the test result
CN1088584A (zh) 1992-12-22 1994-06-29 向明明 从体液中提取纤维结合蛋白的生产工艺
US5352582A (en) 1993-10-28 1994-10-04 Hewlett-Packard Company Holographic based bio-assay
US5597700A (en) 1994-04-28 1997-01-28 California Research, Llc Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method
US5712172A (en) 1995-05-18 1998-01-27 Wyntek Diagnostics, Inc. One step immunochromatographic device and method of use
US5747273A (en) 1996-05-07 1998-05-05 Diagnostic Systems Laboratories, Inc. Immunoassay of total insulin-like growth factor binding protein-1
RU2110800C1 (ru) * 1996-07-02 1998-05-10 Ангалева Елена Николаевна Способ ранней диагностики внутриутробного инфицирования
US6066464A (en) 1996-12-10 2000-05-23 Diagnostic Systems Laboratories, Inc. Immunoassay of IGF family of peptides, their binding proteins and related molecules in dried whole blood filter paper spots
JP3644780B2 (ja) 1996-12-25 2005-05-11 湧永製薬株式会社 免疫学的定量装置
US6248546B1 (en) 1998-03-09 2001-06-19 Diagnostic Systems Laboratories, Inc. Assay of IGFBP complex
DE10121113A1 (de) 2001-04-28 2002-10-31 Gabriele Pecher Genmodifizierte YT Zelllinie und ihre Verwendung
ITMI20030643A1 (it) * 2003-04-01 2004-10-02 Copan Innovation Ltd Tampone per il prelievo di campioni biologici
US8828981B2 (en) * 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
WO2009018607A1 (fr) * 2007-08-03 2009-02-12 Polartechnics Limited Dispositif et procédé pour prélèvement biologique
CA2734736C (fr) * 2008-08-21 2017-02-28 Dna Genotek Inc. Dispositif de reception d'echantillons
CN101805406A (zh) * 2009-06-26 2010-08-18 无锡博慧斯生物医药科技有限公司 人胰岛素样生长因子结合蛋白-1的单克隆抗体、相关的宿主细胞、诊断试剂和诊断试剂盒
CN102053157A (zh) * 2010-11-19 2011-05-11 广州万孚生物技术有限公司 一种胎膜早破快速检测试纸条
US10935555B2 (en) 2016-12-22 2021-03-02 Qiagen Sciences, Llc Determining candidate for induction of labor
US10656164B2 (en) 2016-12-22 2020-05-19 Qiagen Sciences, Llc Screening asymptomatic pregnant woman for preterm birth

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114610B2 (en) * 2002-08-13 2012-02-14 N-Dia, Inc. Devices and methods for detecting amniotic fluid in vaginal secretions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SEUNG MI LEE ET AL: "The clinical significance of a positive Amnisure test in women with preterm labor and intact membranes", JOURNAL OF MATERNAL-FETAL AND NEONATAL MEDICINE, vol. 25, no. 9, 1 January 2012 (2012-01-01), UK, pages 1690 - 1698, XP055261124, ISSN: 1476-7058, DOI: 10.3109/14767058.2012.657279 *
SEUNG MI LEE ET AL: "The clinical significance of a positive Amnisure test(TM) in women with term labor with intact membranes", JOURNAL OF MATERNAL-FETAL AND NEONATAL MEDICINE, vol. 22, no. 4, 1 January 2009 (2009-01-01), UK, pages 305 - 310, XP055279722, ISSN: 1476-7058, DOI: 10.1080/14767050902801694 *

Also Published As

Publication number Publication date
CN107727841B (zh) 2021-05-25
EP2941644B1 (fr) 2019-09-11
EP3637105B1 (fr) 2025-11-12
US20140234987A1 (en) 2014-08-21
US9891233B2 (en) 2018-02-13
JP6465812B2 (ja) 2019-02-06
AU2013371462B2 (en) 2018-12-06
EP3637105A2 (fr) 2020-04-15
AU2013371462A1 (en) 2015-07-30
US11353464B2 (en) 2022-06-07
ES3057344T3 (en) 2026-02-27
HK1245892A1 (zh) 2018-08-31
ES2761575T3 (es) 2020-05-20
EP2941644A1 (fr) 2015-11-11
CN107727841A (zh) 2018-02-23
CN105008925B (zh) 2017-09-26
EP3637105C0 (fr) 2025-11-12
BR112015016027A2 (pt) 2017-07-11
US20220252609A1 (en) 2022-08-11
CA2897053C (fr) 2020-10-13
US20160291031A1 (en) 2016-10-06
EP2941644A4 (fr) 2016-11-09
CN105008925A (zh) 2015-10-28
CA2897053A1 (fr) 2014-07-10
EP4699616A3 (fr) 2026-05-27
US20180156814A1 (en) 2018-06-07
JP2016504592A (ja) 2016-02-12
WO2014107373A1 (fr) 2014-07-10
EP4699616A2 (fr) 2026-02-25

Similar Documents

Publication Publication Date Title
IN2014DN10121A (fr)
SI3178941T1 (sl) Postopek za določanje deleža brezceličnih fetalnih nukleinskih kislin v vzorcu periferne krvi nosečnice in njegova uporaba
EP3495502A3 (fr) Biomarqueurs pour la naissance prématurée
WO2014179765A3 (fr) Nouveaux miarn humains à utiliser dans le diagnostic, le pronostic et la thérapie de maladies et d'états humains
EP4656740A3 (fr) Kit ou dispositif de détection du cancer du sein, et procédé de détection
EP3744859A3 (fr) Biomarqueur à base de microarn utilisable en vue du diagnostic du cancer gastrique
EP4523622A3 (fr) Contrôle non invasif de conditions physiologiques
EA202190075A2 (ru) Анализ транскриптома материнской плазмы с применением массивного параллельного секвенирования рнк
EP3010004A3 (fr) Appareil de sortie d'alarme de véhicule
IN2015DN00678A (fr)
WO2016044889A3 (fr) Procédé et appareil pour déterminer une ouverture de valvule aortique
EP2702934A3 (fr) Appareil et procédé de traitement d'images
EP2905625A3 (fr) Procédé d'égalisation de sonde
RU2010145662A (ru) Способ прогнозирования риска смерти больных хронической сердечной недостаточностью
PL3916105T3 (pl) Metoda i urządzenie do oznaczania stężenia płodowego kwasu nukleinowego we krwi kobiety w ciąży
WO2015173430A3 (fr) Peptide analogue de l'insuline de placenta précoce (pro-epil)
EP3396382A3 (fr) Procédé pour la prédiction non invasive ou le diagnostic non invasif d'une inflammation et d'une infection dans le liquide amniotique de patientes présentant une rupture prématurée de membranes
EP3139170A3 (fr) Procédé d'évaluation d'un patient atteint d'un glioblastome multiforme applicable à un traitement à immunothérapie sur la base des vaccins tumoraux de cellules dendritiques et procédé pour le pronostic de taux de survie dans le patient atteint d'un glioblastome multiforme après traitement
RU2014135019A (ru) Способ диагностики меланомы хориоидеи
PL3593717T3 (pl) Urządzenie do pomiaru glukozy we krwi oraz sposób automatycznego określania jednostki glukozy we krwi
EP2763066A3 (fr) Glucomètre
Li et al. Is it possible to use cell-free fetal DNA to perform prenatal tests for multiple pregnancies?
UA80125U (ru) Способ ранней диагностики формирующейся первичной плацентарной недостаточности
Jian-li Transvaginal ultrasonography and transvaginal three-dimensional ultrasound diagnosis of intrauterine adhesions Value Analysis
CN204500745U (zh) 一种安全型ct检查设备

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 2941644

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20200622BHEP

Ipc: G01N 33/53 20060101AFI20200622BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210129

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230126

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20250612

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AC Divisional application: reference to earlier application

Ref document number: 2941644

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: F10

Free format text: ST27 STATUS EVENT CODE: U-0-0-F10-F00 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251112

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: R17

Free format text: ST27 STATUS EVENT CODE: U-0-0-R10-R17 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251124

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013087159

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: U11

Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20260101

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20251219

Year of fee payment: 13

U01 Request for unitary effect filed

Effective date: 20251205

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI

Effective date: 20251212

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20251219

Year of fee payment: 13

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 3057344

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20260227

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 13

Effective date: 20260225

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20260130

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20260212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20260212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20260312

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20260101

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251112